Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 251

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 251
---
 Newbridge in connection with its opinion. The financial analyses summarized below include information presented in tabular format. In order to fully understand the financial analyses performed by Newbridge, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses performed by Newbridge. Considering the data set forth in the tables below without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of the financial analyses performed by Newbridge.

Financial Analyses. Newbridge employed various methods to analyze the range of values of LBI, including a Comparable Public Company Analysis and a Discounted Cash Flow Analysis.

Comparable Public Company Analysis

To calculate the equity value of Longevity’s three (3) business units, Newbridge first obtained the average Equity Value of six (6) comparable public companies in three different Healthcare sub-verticals identified by Newbridge as an aggregate data set of having the most similarities to Longevity, as a combined entity. The public company comparables were selected using the following criteria: (i) listed on a major U.S. Stock Exchange (NYSE American / NASDAQ / NYSE), (ii) operate in the Healthcare Sector – with different emphases on 3 sub-verticals, (iiia) for Aegeria, focused on “soft tissue repair”, (iiib) for Reflow RVO, focused on “retinal vein occlusion”, (iiic) for Aureva, focused on “stroke care/recovery”, and (iv) were still in the “early / pre-commercialization” stage.

The combined average Equity Values using this analysis was $225.9M.

The tables below summarize certain observed historical financial performance and equity values of the selected public companies were sourced from S&P Capital IQ data as of September 12 th, 2024, as well as qualitative research performed by Newbridge on the company’s business models and lead products.

| 125 |

| Comparable Public Company Analysis 
 Aegeria                            
 Company Name                       |     | Soft Tissue Repair 
 Symbol             |     | 9/12/2024 
 Stock     
 Price     |         |     | Balance Sheet  
 Market         
 Capitalization |       |     | Enterprise 
 Value      |       |     | Income Statement 
 Revenue          
 LTM              |      |     | EBITDA 
 LTM    |      |   |     | Net Income 
 LTM        |      |   |     | Other